Insurers are likely to see more benign tumours than malignant, so, asks Anne Llewellyn, what are the underwriting ramifications?
The human body is made up of millions of cells which divide throughout their lifespan in order to maintain structure, function and growth. The process of cell division (mitosis) is genetically controlled but occasionally this process causes an error in the structure of the genes, and normal cell growth breaks down. If abnormal multiplication of cells (neoplasia) takes place it can result in a growth called a neoplasm, more commonly known as a tumour - of which there are two categories, malignant and benign. Characteristics of malignant tumours - invade surrounding cell tissue, ta...
To continue reading this article...
Join Professional Adviser
- Unlimited access to real-time news, industry insights and market intelligence.
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters.
- Make smart business decisions with the latest developments in regulation, investing retirement and protection.
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes.